Autologous Plasmablasts not checked

Immusoft of CA, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Autologous plasmablasts (B cells) engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty (SB) transposon system.”In the company’s words, NCT05682144 on ClinicalTrials.gov
Tested for
Mucopolysaccharidosis IH/S, Mucopolysaccharidosis IS
Main trialPhase 1
“A first-in-human study using ISP-001 in patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.”In the company’s words, NCT05682144 on ClinicalTrials.gov

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 1 Jun 2029 ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Autologous Plasmablasts

Following is part of Solo: you see every change to Autologous Plasmablasts the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in